Guggenheim Capital LLC Lowers Stock Holdings in Masimo Co. (NASDAQ:MASI)

Guggenheim Capital LLC decreased its position in shares of Masimo Co. (NASDAQ:MASI) by 25.3% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,771 shares of the medical equipment provider’s stock after selling 1,616 shares during the quarter. Guggenheim Capital LLC’s holdings in Masimo were worth $880,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in Masimo by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 4,775,660 shares of the medical equipment provider’s stock worth $695,050,000 after purchasing an additional 71,918 shares in the last quarter. State Street Corp lifted its stake in Masimo by 1.6% in the 1st quarter. State Street Corp now owns 1,730,991 shares of the medical equipment provider’s stock worth $251,928,000 after purchasing an additional 27,261 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Masimo by 92.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 856,664 shares of the medical equipment provider’s stock worth $111,940,000 after purchasing an additional 410,793 shares in the last quarter. Geode Capital Management LLC lifted its stake in Masimo by 4.7% in the 4th quarter. Geode Capital Management LLC now owns 703,196 shares of the medical equipment provider’s stock worth $103,920,000 after purchasing an additional 31,667 shares in the last quarter. Finally, Schroder Investment Management Group lifted its stake in Masimo by 44.9% in the 4th quarter. Schroder Investment Management Group now owns 577,277 shares of the medical equipment provider’s stock worth $85,408,000 after purchasing an additional 178,753 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Stock Performance

Shares of NASDAQ:MASI opened at $113.59 on Tuesday. The company has a market capitalization of $6.00 billion, a price-to-earnings ratio of 53.08 and a beta of 0.81. Masimo Co. has a 12 month low of $105.50 and a 12 month high of $198.00. The firm’s 50-day moving average is $127.61 and its 200 day moving average is $157.78. The company has a current ratio of 2.11, a quick ratio of 1.16 and a debt-to-equity ratio of 0.68.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, August 8th. The medical equipment provider reported $0.62 EPS for the quarter, missing the consensus estimate of $0.86 by ($0.24). The firm had revenue of $455.30 million for the quarter, compared to the consensus estimate of $478.27 million. Masimo had a net margin of 5.30% and a return on equity of 15.79%. The business’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.35 earnings per share. Research analysts predict that Masimo Co. will post 3.46 EPS for the current year.

Analyst Ratings Changes

Several analysts have commented on the stock. StockNews.com cut shares of Masimo from a “hold” rating to a “sell” rating in a research note on Friday, August 25th. BTIG Research reduced their target price on shares of Masimo from $200.00 to $153.00 in a report on Tuesday, July 18th. Needham & Company LLC restated a “buy” rating and issued a $136.00 target price on shares of Masimo in a report on Wednesday, August 9th. Wells Fargo & Company reduced their target price on shares of Masimo from $126.00 to $110.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 9th. Finally, Stifel Nicolaus downgraded shares of Masimo from a “buy” rating to a “hold” rating and reduced their target price for the stock from $205.00 to $120.00 in a report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $151.33.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and O3 regional oximetry.